What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Ovarian cancer, Surgery and Gynecologic oncology.
His Internal medicine study is mostly concerned with Bevacizumab, Chemotherapy, Clinical trial, Randomized controlled trial and Hazard ratio.
His studies deal with areas such as Cancer and Urology as well as Chemotherapy.
His Oncology study incorporates themes from Placebo, Clinical endpoint, Gynecology, Carcinoma and Stage.
Bradley J. Monk has researched Ovarian cancer in several fields, including Malignancy, Progression-free survival, Gene expression, Bioinformatics and Breast cancer.
His Surgery research incorporates themes from Tolerability and Drug development.
His most cited work include:
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer (1159 citations)
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (954 citations)
- Improved Survival with Bevacizumab in Advanced Cervical Cancer (717 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Gynecologic oncology.
His research on Internal medicine often connects related areas such as Surgery.
His Oncology research is multidisciplinary, relying on both Advanced ovarian cancer, Clinical endpoint, Recurrent Ovarian Cancer and Trabectedin.
His Ovarian cancer study also includes fields such as
- Cancer research which connect with Platinum resistant,
- Placebo which is related to area like Gastroenterology.
His research in Chemotherapy intersects with topics in Biomarker, Serous fluid and Disease.
His Gynecologic oncology research incorporates elements of Randomized controlled trial, Quality of life, Group study, Proportional hazards model and Performance status.
He most often published in these fields:
- Internal medicine (75.05%)
- Oncology (64.27%)
- Ovarian cancer (30.23%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (75.05%)
- Oncology (64.27%)
- Ovarian cancer (30.23%)
In recent papers he was focusing on the following fields of study:
Bradley J. Monk spends much of his time researching Internal medicine, Oncology, Ovarian cancer, Chemotherapy and In patient.
His work is connected to Bevacizumab, Clinical endpoint, Adverse effect, Newly diagnosed and Cervical cancer, as a part of Internal medicine.
His Bevacizumab research includes elements of Pembrolizumab, Gynecologic oncology and Paclitaxel.
His Oncology study combines topics from a wide range of disciplines, such as Trabectedin, Poly ADP ribose polymerase, Advanced ovarian cancer, Biomarker and Recurrent Ovarian Cancer.
While the research belongs to areas of Ovarian cancer, he spends his time largely on the problem of Clinical trial, intersecting his research to questions surrounding Cancer research.
His Chemotherapy research is multidisciplinary, incorporating elements of Debulking, Interim analysis, Serous fluid and Toxicity.
Between 2019 and 2021, his most popular works were:
- MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. (7 citations)
- Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. (6 citations)
- Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study (6 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Bradley J. Monk mainly focuses on Internal medicine, Oncology, Ovarian cancer, Cancer and Clinical endpoint.
In general Internal medicine, his work in Phases of clinical research, Cervical cancer, Chemotherapy and Newly diagnosed is often linked to In patient linking many areas of study.
His work deals with themes such as Metastatic cervical cancer, Adverse effect, Bevacizumab, Recurrent disease and Recurrent Ovarian Cancer, which intersect with Oncology.
In his study, Mesothelin, Immunohistochemistry, Tolerability and Monoclonal antibody is strongly linked to Biomarker, which falls under the umbrella field of Ovarian cancer.
His work in Cancer covers topics such as Intensive care medicine which are related to areas like Targeted therapy and Health professionals.
The study incorporates disciplines such as Carboplatin, Placebo and Randomization in addition to Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
